Genentech's EVP of research and early development Aviv Regev at #JPM23 (Adrien Villez for Endpoints News)
December 11, 2023 09:42 AM EST
People
R&D
AI

Ex­clu­sive: Aviv Regev talks three years of lead­ing Genen­tech’s re­search, the fu­ture of AI, and not mak­ing No­bel pre­dic­tions

Andrew Dunn

Senior Biopharma Correspondent

SOUTH SAN FRAN­CIS­CO — In 2020, Aviv Regev end­ed an es­teemed 14-year run at the Broad In­sti­tute to jump in­to the drug in­dus­try, be­com­ing Genen­tech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times